Question 1

What are the potential benefits of erlotinib compared to standard chemotherapy for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 clinical trial (NCT00085839). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I expect from erlotinib and how do they compare to chemotherapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 clinical trial (NCT00085839). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my performance status affect my treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 clinical trial (NCT00085839). Contact the study team or your healthcare provider for specific answers.

Question 4

What are the logistics of participating in this trial, such as visit frequency and treatment duration?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 clinical trial (NCT00085839). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any specific tests or monitoring required during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 clinical trial (NCT00085839). Contact the study team or your healthcare provider for specific answers.

Question 6

What should I consider when deciding between erlotinib and standard chemotherapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 clinical trial (NCT00085839). Contact the study team or your healthcare provider for specific answers.

What this study is about